PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- Vutisiran HCRU and discontinuation

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- D28 sTTR association with CVMCVH

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- Atrial fibrillation at baseline and clinical outcomes

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- ACM and ACMCVH Subgroup Analysis

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- Variant ACM and First CVH

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- p.V142I (V122I) ACM analysis

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- NT-proBNP and Atrial Fibrillation

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- ACM and CVH (early HF with and without AF)

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- VA Prevalence Geographic Disparities

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- Demographic Disparities